These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1481452)

  • 21. [Long-term selegiline tolerance in the treatment of Parkinson's disease].
    Vermersch P; Petit H
    Therapie; 1992; 47(1):75-8. PubMed ID: 1523599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rasagiline as a therapy for Parkinson's disease (PD).
    Hermanowicz N
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
    [No Abstract]   [Full Text] [Related]  

  • 23. The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
    Tábi T; Szökő E; Vécsei L; Magyar K
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):629-36. PubMed ID: 23506388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selegiline and mortality in Parkinson's disease: another view.
    Lees AJ; Head J; Shlomo YB
    Ann Neurol; 1997 Feb; 41(2):282-3. PubMed ID: 9029081
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases.
    Shapiro MA; Chang YL; Munson SK; Okun MS; Fernandez HH
    Parkinsonism Relat Disord; 2006 Sep; 12(6):392-5. PubMed ID: 16730214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies.
    Langston JW
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 61-6; discussion 67-9. PubMed ID: 2120617
    [No Abstract]   [Full Text] [Related]  

  • 28. [A new drug for Parkinson's disease: selegiline (Eldeprine). Copenhagen, January 26-27, 1989].
    D'Anglejan-Chatillon J
    Rev Prat; 1989 Oct; 39(22):1978. PubMed ID: 2510243
    [No Abstract]   [Full Text] [Related]  

  • 29. Parkinson's disease: consider pallidotomy as a therapeutic option.
    Iacano RP; Mohamed AS; Schoonenberg T
    Geriatrics; 1996 Mar; 51(3):26. PubMed ID: 8641588
    [No Abstract]   [Full Text] [Related]  

  • 30. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
    Dubois B; Montastruc JL
    Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
    [No Abstract]   [Full Text] [Related]  

  • 31. MAO-B inhibitors in Parkinson's disease.
    Olanow CW
    Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
    [No Abstract]   [Full Text] [Related]  

  • 32. Selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    J Neural Transm Suppl; 1987; 25():105-13. PubMed ID: 3123597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selegiline hydrochloride and cognition.
    Lees AJ
    Acta Neurol Scand Suppl; 1991; 136():91-4. PubMed ID: 1801544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
    LeWitt PA
    Clin Neuropharmacol; 2007; 30(5):305-7. PubMed ID: 17909310
    [No Abstract]   [Full Text] [Related]  

  • 35. Retention rate of selegiline in early Parkinson's disease: a retrospective survey.
    Keränen T; Mattila T; Luukkaala T; Kuusisto H
    Int J Clin Pract; 2012 Oct; 66(10):1014. PubMed ID: 22994335
    [No Abstract]   [Full Text] [Related]  

  • 36. Experience with selegiline in the treatment of Parkinson's disease.
    Poewe W; Gerstenbrand F; Ransmayr G
    J Neural Transm Suppl; 1987; 25():131-5. PubMed ID: 3123599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluoxetine and selegiline--lack of significant interaction.
    Waters CH
    Can J Neurol Sci; 1994 Aug; 21(3):259-61. PubMed ID: 8000982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of selegiline on cognitive functions in Parkinson's disease.
    Dixit SN; Behari M; Ahuja GK
    J Assoc Physicians India; 1999 Aug; 47(8):784-6. PubMed ID: 10778622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?
    Olanow CW; Calne D
    Neurology; 1992 Apr; 42(4 Suppl 4):13-26; discussion 41-8. PubMed ID: 1584429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selegiline, pregnancy, and Parkinson's disease.
    Kupsch A; Oertel WH
    Mov Disord; 1998 Jan; 13(1):175-6. PubMed ID: 9452347
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.